title: Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs.
abstract: Phenylethylthiazolylthiourea (PETT) derivatives have been identified as a new series of non-nucleoside inhibitors of HIV-1 RT. Structure-activity relationship studies of this class of compounds resulted in the identification of N-[2-(2-pyridyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea hydrochloride (trovirdine; LY300046.HCl) as a highly potent anti-HIV-1 agent. Trovirdine is currently in phase one clinical trials for potential use in the treatment of AIDS. Extension of these structure-activity relationship studies to identify additional compounds in this series with improved properties is ongoing. A part of this work is described here. Replacement of the two aromatic moieties of the PETT compounds by various substituted or unsubstituted heteroaromatic rings was investigated. In addition, the effects of multiple substitution in the phenyl ring were also studied. The antiviral activities were determined on wild-type and constructed mutants of HIV-1 RT and on wild-type HIV-1 and mutant viruses derived thereof, Ile100 and Cys181, in cell culture assays. Some selected compounds were determined on double-mutant viruses, HIV-1 (Ile 100/Asn103) and HIV-1 (Ile100/Cys181). A number of highly potent analogs were synthesized. These compounds displayed IC50's against wild-type RT between 0.6 and 5 nM. In cell culture, these agents inhibited wild-type HIV-1 with ED50's between 1 and 5 nM in MT-4 cells. In addition, these derivatives inhibited mutant HIV-1 RT (Ile 100) with IC50's between 20 and 50 nM and mutant HIV-1 RT (Cys 181) with IC50's between 4 and 10 nM, and in cell culture they inhibited mutant HIV-1 (Ile100) with ED50's between 9 and 100 nM and mutant HIV-1 (Cys181) with ED50's between 3 and 20 nM.
authors.affiliation: Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA.
authors.forename: A S
authors.initials: AS
authors.lastname: Cantrell
authors.forename: P
authors.initials: P
authors.lastname: Engelhardt
authors.forename: M
authors.initials: M
authors.lastname: Högberg
authors.forename: S R
authors.initials: SR
authors.lastname: Jaskunas
authors.forename: N G
authors.initials: NG
authors.lastname: Johansson
authors.forename: C L
authors.initials: CL
authors.lastname: Jordan
authors.forename: J
authors.initials: J
authors.lastname: Kangasmetsä
authors.forename: M D
authors.initials: MD
authors.lastname: Kinnick
authors.forename: P
authors.initials: P
authors.lastname: Lind
authors.forename: J M
authors.initials: JM
authors.lastname: Morin
authors.forename: M A
authors.initials: MA
authors.lastname: Muesing
authors.forename: R
authors.initials: R
authors.lastname: Noreén
authors.forename: B
authors.initials: B
authors.lastname: Oberg
authors.forename: P
authors.initials: P
authors.lastname: Pranc
authors.forename: C
authors.initials: C
authors.lastname: Sahlberg
authors.forename: R J
authors.initials: RJ
authors.lastname: Ternansky
authors.forename: R T
authors.initials: RT
authors.lastname: Vasileff
authors.forename: L
authors.initials: L
authors.lastname: Vrang
authors.forename: S J
authors.initials: SJ
authors.lastname: West
authors.forename: H
authors.initials: H
authors.lastname: Zhang
mesh_terms: D000818:Animals; D019380:Anti-HIV Agents / Q000737:chemistry / Q000494:pharmacology*; D002478:Cells, Cultured; D054303:HIV Reverse Transcriptase / Q000037:antagonists & inhibitors*; D007364:Intercalating Agents / Q000494:pharmacology*; D013329:Structure-Activity Relationship; D013844:Thiazoles / Q000737:chemistry / Q000494:pharmacology*; D013890:Thiourea / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology
chemical_list: D019380:Anti-HIV Agents; D007364:Intercalating Agents; C095795:LY 73497; D013844:Thiazoles; D054303:HIV Reverse Transcriptase; D013890:Thiourea